🔎 Trials Near Me

Home › Glioma › Tennessee

Glioma clinical trials in Tennessee

8 studies for Glioma are looking for participants at sites in Tennessee.

Cities in Tennessee

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

  • East Tennessee Childrens Hospital, Knoxville
  • Saint Jude Children's Research Hospital, Memphis
  • The Children's Hospital at TriStar Centennial, Nashville
RecruitingPhase 1/2
12 Months – 21 Years · All sexes · Updated Sep 30, 2026 · NCT05099003

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

  • St. Jude Children's Research Hospital, Memphis
RecruitingPhase 1/2
Up to age 25 · All sexes · Updated Sep 25, 2026 · NCT04094610

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

  • Vanderbilt-Ingram Cancer Center, Nashville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT05303519

A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3

  • SCRI Oncology Partners, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT05916313

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  • SCRI - TriStar Medical Group Children's Specialists, Nashville
  • SCRI Oncology Partners, Nashville
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

  • Vanderbilt University Medical Center, Nashville
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Jul 1, 2026 · NCT07210632

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

  • St. Jude Children's Research Hospital, Memphis
RecruitingPhase 2
Up to age 3 · All sexes · Updated May 13, 2026 · NCT06528691

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

  • SCRI Oncology Partners, Nashville
  • Vanderbilt-Ingram Cancer Center, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 20, 2026 · NCT06326411

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.